# Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial

***Running title: Switch to once-weekly icodec in type 2 diabetes***

Harpreet S. Bajaj, MD1,2 Richard M. Bergenstal, MD3 Andreas Christoffersen, PhD4 Melanie J. Davies, MD5,6 Amoolya Gowda, MD4 Joakim Isendahl, PhD4 Ildiko Lingvay, MD7 Peter A. Senior, PhD8 Robert J. Silver, MD9 Roberto Trevisan, PhD10 and Julio Rosenstock, MD11

1LMC Diabetes & Endocrinology, Brampton, Ontario, Canada

2Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada

3International Diabetes Center at HealthPartners, Minneapolis, MN

4Novo Nordisk A/S, Søborg, Denmark

5Diabetes Research Centre, University of Leicester, Leicester, UK

6NIHR Leicester Biomedical Research Centre, Leicester, UK

7University of Texas Southwestern Medical Center, Dallas, TX

8University of Alberta, Edmonton, Alberta, Canada

9Southern New Hampshire Diabetes and Endocrinology, Nashua, NH

10Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy

11Dallas Diabetes Research Center, Medical City, Dallas, TX

Corresponding author: Harpreet S. Bajaj, LMC Diabetes & Endocrinology, Brampton, Ontario L6S 0C6, Canada. Telephone number (1) 905-595-0560. Fax number (1) 905-595-0562. Email **harpreet.bajaj@lmc.ca**

Clinical trial ref. no. NCT03922750, clinicaltrials.gov

This article includes supplementary material online at https://

Abstract

**OBJECTIVE**Insulin icodec (icodec) is a novel once-weekly basal insulin analog. This trial investigated two approaches for switching to icodec versus once-daily insulin glargine U100 (IGlar U100) in people with type 2 diabetes receiving daily basal insulin and ≥1 oral glucose-lowering medication.

**RESEARCH DESIGN AND METHODS**
This multicenter, open-label, treat-to-target phase 2 trial randomized (1:1:1) eligible basal-insulin-treated (total daily dose 10–50 U) people with type 2 diabetes (HbA1c 7.0–10.0% [53.0–13.3 mmol/mo]) to icodec with an initial 100% loading dose (where only the first dose was doubled; icodec LD), icodec with no loading dose (icodec NLD) or IGlar U100 for 16 weeks. Primary endpoint was percent time in range (TIR; 3.9–10.0 mmol/L [70–180 mg/dL]) during weeks 15 and 16, measured using continuous glucose monitoring. Key secondary endpoints included HbA1c,adverse events (AEs) and hypoglycemia.

**RESULTS**
Estimated mean TIR during weeks 15 and 16 was 72.9% (icodec LD; *n* = 54), 66.0% (icodec NLD; *n* = 50) and 65.0% (IGlar U100; *n* = 50), with a statistically significant difference favoring icodec LD versus IGlar U100 (7.9%-points, 95% CI 1.8 to 13.9%). Mean HbA1c reduced from 7.9% (62.8 mmol/mol) at baseline to 7.1% ([54.4 mmol/mol] icodec LD) and 7.4% ([57.6 mmol/mol] icodec NLD and IGlar U100); incidences and rates of AEs and hypoglycemic episodes were comparable.

**CONCLUSIONS**
Switching from daily basal insulin to once-weekly icodec was well tolerated and provided effective glycemic control. Loading dose use when switching to once-weekly icodec significantly increased percent TIR during weeks 15 and 16 versus once-daily IGlar U100, without increasing hypoglycemia risk.

# Introduction

Although many individuals with type 2 diabetes require insulin therapy at some point (1; 2), glycemic control remains inadequate in many patients (3). This could be attributed to the need for frequent injections resulting in poor adherence, and concerns about complex dosing, the adverse effects of hypoglycemia and weight gain, and treatment costs (2; 4-8). Once-daily basal insulin analogs have addressed some of these concerns (9; 10), but research suggests that people with type 2 diabetes would value a further reduction in dosing frequency of injectable therapies to once weekly, which may improve convenience, adherence and quality of life. In turn, these improvements may lead to better glycemic control (11).

Insulin icodec (icodec) is a novel basal insulin analog for subcutaneous administration for the treatment of diabetes. It has stable pharmacokinetic and pharmacodynamic profiles, with a half‑life of approximately 1 week , supporting once-weekly administration (12). The long half-life of icodec can be attributed to its strong, reversible albumin binding, reduced enzymatic degradation and slow receptor-mediated clearance (13). After subcutaneous injection and absorption into the circulation, icodec monomers bind to albumin to form an essentially inactive depot, from which icodec molecules slowly reach insulin receptors at target tissues to stimulate glucose lowering. With each weekly injection the pool of albumin-bound icodec gradually increases, until steady state is reached after 3–4 weeks when the full glucose-lowering effect is achieved and insulin clearance matches administered insulin dose. At steady state, a slow, continuous release of icodec from the inactive albumin-bound depot provides effective glucose lowering throughout the week, (13) which was shown to be near evenly distributed across a 1-week dosing interval (12). In a phase 2 trial in insulin-naïve individuals with type 2 diabetes, once-weekly icodec resulted in a similar glucose-lowering effect and safety profile compared with once-daily insulin glargine (IGlar) U100(14).

Theoretically, individuals switching from a daily basal insulin regimen may require additional insulin to maintain glycemic control during the initial weeks after switch, until steady state is reached. Pharmacokinetic and pharmacodynamic modeling data, based on clinical pharmacology studies of icodec, suggest that when switching from daily to once-weekly basal insulin, adding a supplemental dose of icodec (a ‘loading dose’) to the first dose may prevent any transient deterioration in fasting glucose levels before steady state is achieved without jeopardizing safety, as this additional dose would add to the inactive albumin-bound reservoir of icodec.

The aim of the current trial was to evaluate the effect on glycemic control and safety of two different approaches of switching to once-weekly icodec, with and without a loading dose, versus once-daily IGlar U100 in people with type 2 diabetes inadequately controlled on basal insulin plus at least one oral glucose-lowering medication.

# RESEARCH DESIGN AND METHODS

## Research Design

This exploratory, multicenter, open-label, randomized, active-controlled, parallel‑group, treat-to-target phase 2 trial was conducted in 34 centers located in Canada, the Czech Republic, Germany, Italy and the USA. The trial consisted of a 2-week screening period, 16 weeks of randomized treatment and 5 weeks of follow-up (Supplementary Figure S1).

The trial was conducted in accordance with the guidelines for Good Clinical Practice of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, and the Declaration of Helsinki. The protocol, consent form and other relevant documents were approved by the appropriate independent review boards or independent ethics committees.

## Patients

The trial population comprised basal-insulin-treated individuals with type 2 diabetes recruited between May 9, 2019 and August 15, 2019 with the last follow up occurring on January 27, 2020. Eligible participants, aged 18–75 years with a BMI of ≤40 kg/m2 and a centrally assessed HbA1c of 7.0–10.0% (53.0–85.8 mmol/mol),were treated for at least 90 days before screening with stable doses of metformin, with or without concomitant use of dipeptidyl peptidase 4 inhibitors (DPP4is) and/or sodium–glucose cotransporter 2 inhibitors (SGLT2is), along with basal insulin (once or twice daily) with a total daily dose of 10–50 units (U). Full details of inclusion and exclusion criteria are provided in Supplementary Table S1. All participants provided written informed consent to participate in the trial.

**Randomization**

After screening, participants were randomized (1:1:1) to once‑weekly icodec with an initial 100% loading dose (icodec LD), once-weekly insulin icodec with no loading dose (icodec NLD) or once‑daily IGlar U100. Randomization was performed centrally using an interactive web response system. Participants were assigned to the next available treatment according to the randomization schedule and stratified based on SGLT2i use (yes or no) and type of pre-trial insulin therapy (i.e., receiving once-daily basal insulin, or receiving twice-daily basal insulin or once-daily IGlar U300).

## Procedures

The initial dose of the trial products was based on the pre-trial insulin daily doses. Participants who had been receiving once-daily basal insulin (except for those receiving IGlar U300) at baseline underwent a ‘unit to unit’ switch to icodec (700 U/mL; pre-filled pen-injector, Novo Nordisk, Bagsvaerd, Denmark) or IGlar U100 (100 U/mL; SoloSTAR® pre-filled pen-injector, Sanofi, Paris, France) based on their daily dose; to derive the equivalent once-weekly dose for the icodec LD and NLD groups, the daily dose was multiplied by seven. For those who had been receiving twice-daily basal insulin or once-daily IGlar U300 at baseline, starting doses of IGlar U100 were decreased by 20% to minimize the post-switch hypoglycemia risk; for the icodec LD and NLD groups, the dose was similarly decreased by 20% and then multiplied by seven to derive the once-weekly dose. Participants in the icodec LD group received an initial 100% loading dose with the first dose of icodec (i.e., the first weekly dose was doubled), then it was reverted to the calculated weekly dose at week 2 (Supplementary Figure S1B). Icodec had to be taken subcutaneously once weekly on the same day each week, while IGlar U100 had to be taken subcutaneously once daily at any time of the day but at the same time every day.

A treat-to-target approach was used to ensure optimal titration of insulin; doses of icodec and IGlar U100 were titrated weekly to achieve a pre-breakfast self-measured blood glucose (SMBG) target of 4.4–7.2 mmol/L (80–130 mg/dL). Participants measured SMBG levels (FreeStyle Precision/Optium Neo Meter; Abbott GmbH & Co. KG, Abbott Diabetes Care) each day before breakfast. Doses were up-titrated weekly by 4 U per day (IGlar U100) or 28 U per week (icodec LD and icodec NLD) if the mean of the three most recent pre-breakfast SMBG values in a week was >7.2 mmol/L (>130 mg/dL). However, if any one of the three pre-breakfast SMBG values was <4.4 mmol/L (<80 mg/dL), the insulin doses were down-titrated 4 U per day (IGlar U100) or 28 U per week (icodec LD and icodec NLD).

Background oral glucose-lowering drugs were continued unchanged throughout the trial unless there were safety concerns in the opinion of the investigator.

## Outcomes

Participants wore a continuous glucose monitoring (CGM) system (Dexcom G6; DexCom, Inc., San Diego, California, USA) throughout the screening and treatment periods; sensors were changed weekly. CGM data were blinded for both participants and investigators and were not used for insulin dose titration or reporting of hypoglycemic episodes. Participants were asked to measure SMBG if they experienced symptoms suggestive of hypoglycemia at any time of the day.

The primary endpoint was percent time in range (TIR; 3.9–10.0 mmol/L [70–180 mg/dL]), measured by CGM, during weeks 15 and 16 of treatment. Supportive secondary efficacy endpoints were changes in HbA1c, fasting plasma glucose (FPG) and body weight from baseline to week 16, and weekly insulin doses during weeks 15 and 16 of treatment. Safety endpoints were number of on-treatment adverse events (AEs) from baseline to week 21, and number of self-reported hypoglycemic events documented by SMBG or by requirement for external assistance for recovery. Hypoglycemic events were classified as: level 1 (blood glucose <3.9 mmol/L and ≥3.0 mmol/L [<70 mg/dL and ≥54 mg/dL]); a combination of level 2 (blood glucose <3.0 mmol/L [<54 mg/dL]) and level 3 (hypoglycemia with severe cognitive impairment requiring external assistance for recovery); or level 3 alone.(15) AEs of special interest were major cardiovascular AEs, hypersensitivity and injection-site reactions, and death; these were reviewed by a blinded independent adjudication committee.

## Statistical Analysis

The sample size was chosen as the number of patients required for the 95% CI for TIR 3.9–10.0 mmol/L (70–80 mg/dL) of any pairwise comparison to have a width of 2.5 hours/24 hours (corresponding to a difference of 10%-points), with a probability of 80%, based on an assumed standard deviation of 3.0 hours/24 hours (corresponding to 12%); based on this, 50 participants per treatment arm were required. This trial was exploratory in nature and intended to inform the design of the phase 3 program; therefore, the power was not calculated.

TIR during weeks 15 and 16 for each individual was calculated as the number of recorded measurements in the range 3.9–10.0 mmol/L (70–180 mg/dL) divided by the total number of recorded measurements over 14 days, multiplied by 100.

The primary estimand (trial product estimand) was defined as the mean difference in the primary endpoint between each icodec group and IGlar U100 for all randomized participants, if they had adhered to the randomized insulin treatment without initiation of rescue medication (initiation of insulin treatment other than the randomized treatment) and had recorded ≥70% of the planned CGM measurements during weeks 15 and 16. A more detailed explanation is provided in the online supplementary material. For TIR, the response throughout the last 2 weeks of treatment (weeks 15 and 16) was analyzed using an ANCOVA model with randomized treatment, pre-trial insulin treatment and SGLT2i use as fixed factors, and baseline TIR as covariate. Missing endpoint values were imputed by multiple imputation using data from participants in the same randomized group, based on an ANCOVA model with baseline TIR as a covariate. Each imputed data set was analyzed separately and estimates were then combined using Rubin’s rule (16). Supportive secondary efficacy endpoints were analyzed in the same way as the primary endpoint, except for the mean weekly insulin dose during the last 2 weeks of treatment, which was log-transformed and analyzed using an ANOVA model. Missing data for secondary endpoints were imputed based on data from participants in the same randomized group, using a sequential conditional regression approach including all post-baseline values; Markov Chain Monte-Carlo methods were used for imputing intermittent missing values. Because this is a phase 2 trial and it is exploratory in nature, no adjustments were made for multiplicity. The number of hypoglycemic events was analyzed using a negative binomial regression model with log link. The model included treatment, pre-trial insulin treatment and SGLT2i use as fixed factors, and the logarithm of the time period for which the hypoglycemic episodes were considered as an offset.

The on-treatment period was defined as the period from the date of first trial drug dose until the last follow-up visit or the last dosing day of randomized treatment plus 5 weeks (for IGlar U100) or 6 weeks (for icodec), whichever came first, and represents the time period during which participants are considered to be exposed to the trial product.

The full analysis set consisted of all randomized participants. The safety analysis set consisted of all participants exposed to at least one dose of trial product. Data were analyzed using SAS software 9.4. No data monitoring committee oversaw the trial. This trial was registered on the clinicaltrials.gov website (NCT03922750).

# Results

Of 222 people screened, 154 individuals were randomized (icodec LD, *n* = 54; icodec NLD, *n* = 50; IGlar U100, *n* = 50) and 152 completed the 16-week treatment period (Supplementary Figure S2). All 154 trial participants were included in the efficacy and safety analyses. Eight participants had missing or <70% CGM measurements during the last 2 weeks of treatment (weeks 15 and 16) and required imputation of data for the primary endpoint: one for icodec LD, five for icodec NLD and two for IGlar U100. Three participants started insulin aspart as a rescue medication during the trial; two participants (one each for icodec NLD and IGlar U100) started insulin aspart on the same day or after the last dose of trial drug, and one participant (icodec NLD) started insulin aspart on day 30. Separately, one participant (IGlar U100) discontinued sitagliptin/metformin treatment during the trial.

Baseline demographics and clinical characteristics were generally similar between groups (Table 1 and Supplementary Table S2): most participants were male (72.1%); the mean age was 61.7 years; the mean duration of type 2 diabetes was 15.1 years; the mean ± SD HbA1c was 7.9% ± 0.7 (62.8 ± 7.7 mmol/mol); the mean ± SD FPG was 8.0 ± 2.1 mmol/L (144 ± 37 mg/dL); and the majority of participants (57.8%) were taking more than one oral glucose-lowering drug. IGlar U100 was the most used basal insulin at screening (59.7%).

The estimated mean TIR during weeks 15 and 16 was 72.9% for icodec LD, 66.0% for icodec NLD and 65.0% for IGlar U100, representing estimated changes from baseline in TIR of 15.4%-points, 8.6%-points and 7.6%-points for icodec LD, icodec NLD and IGlar U100, respectively. These correspond to estimated changes from baseline in TIR of approximately 3 hours and 42 minutes, 2 hours and 4 minutes and 1 hour and 49 minutes per day, respectively. The primary endpoint of TIR was statistically significantly greater for the icodec LD group compared with the IGlar U100 group (estimated treatment difference [ETD], 7.88%-points, 95% CI 1.83 to 13.93; *P* = 0.01) and similar between the icodec NLD group and the IGlar U100 group (ETD, 1.01%-points, 95% CI −5.33 to 7.5; *P* = non-significant [NS]) (Figure 1).

HbA1c levels reduced in all treatment groups during the trial (Figure 2A). At week 16, estimated mean HbA1c levels were 7.1% (54.4 mmol/mol), 7.4% (57.6 mmol/mol) and 7.4% (56.9 mmol/mol) in the icodec LD, icodec NLD and IGlar U100 groups, respectively. The estimated mean change from baseline at week 16 was −0.8%-points (–8.4 mmol/mol) in the icodec LD group, −0.5%-points (–5.2 mmol/mol) in the icodec NLD group and −0.5%-points (–5.9 mmol/mol) in the IGlar U100 group, with no statistically significant differences between icodec groups and the IGlar U100 group (ETD, icodec LD vs IGlar U100, −0.23%-points, 95% CI −0.49 to 0.02 [–2.53 mmol/mol, 95% CI –5.33 to 0.27]; *P* = NS; ETD, icodec NLD vs. IGlar U100, 0.07%-points, 95% CI −0.19 to 0.33 [0.73 mmol/mol, 95% CI –2.11 to 3.57]; *P* = NS). After 16 weeks of treatment, the proportions of participants achieving a target HbA1c of <7.0% (53 mmol/mol) were 44.2%, 25.0% and 30.6% for the icodec LD, icodec NLD and IGlar U100 groups, respectively (no statistical analyses were performed).

Compared with baseline, FPG was lower at week 16 in all treatment groups; estimated mean values at week 16 were 7.3 mmol/L (132 mg/dL), 7.2 mmol/L (129 mg/dL) and 7.4 mmol/L (134 mg/dL) for icodec LD, icodec NLD and IGlar U100, respectively (Figure 2B). The estimated mean change from baseline was similar between icodec LD and IGlar U100 groups (−0.7 mmol/L vs. −0.6 mmol/L: ETD, −0.12 mmol/L, 95% CI −0.74 to 0.50; *P* = NS [–12 mg/dL vs. –10 mg/dL: ETD, –2.20 mg/dL, 95% CI –13.33 to 8.94; *P* = NS]) and also between icodec NLD and IGlar U100 groups (−0.8 mmol/L vs. −0.6 mmol/L: ETD −0.26 mmol/L, 95% CI −0.90 to 0.38; *P* = NS [−15 mg/dL vs. −10 mg/dL: ETD −4.74 mg/dL, 95% CI −16.28 to 6.80; *P* = NS]). At week 8, mean observed FPG values were similar between icodec LD and IGlar U100 groups (7.4 mmol/L vs. 7.3 mmol/L [133 mg/dL vs. 132 mg/dL]) but slightly higher for the icodec NLD group (8.2 mmol/L [144 mg/dL]). No statistical analyses at week 8 were performed.

For comparison, the weekly changes in fasting (pre-breakfast) SMBG levels (measured as part of the titration process and not as an endpoint) are shown in Figure 2C. SMBG levels decreased in all treatment groups over the course of the trial; however, in the icodec NLD group, mean SMBG levels were seen to increase slightly versus baseline during the first 3 weeks before reverting to levels similar to those for the icodec LD and IGlar U100 groups at about week 5.

Insulin dose gradually increased during the trial in all groups (Figure 2D). During the last 2 weeks of treatment (weeks 15 and 16), the estimated mean weekly doses were 191 U (2.18 U/kg), 242 U (2.81 U/kg) and 196 U (2.27 U/kg) for icodec LD, icodec NLD and IGlar U100, respectively (estimated treatment ratio [ETR] icodec LD vs IGlar U100, 0.98 U, 95% CI 0.78 to 1.23, *P* = NS [0.96 U/kg, 95% CI 0.78 to 1.19, *P*=NS]; ETR icodec NLD vs IGlar U100, 1.24 U, 95% CI 0.98 to 1.56, *P* = NS [1.24 U/kg, 95% CI 1.00 to 1.54, *P*=0.047]).

The change in body weight during the trial is shown in Supplementary Figure S3. Estimated mean changes from baseline were 0.6 kg, 1.3 kg and 0.1 kg in the icodec LD, icodec NLD and IGlar U100 groups, respectively. Although the mean change in body weight from baseline was not statistically significantly different between icodec LD and IGlar U100 groups (ETD, 0.51 kg, 95% CI −0.44 to 1.47; *P* = NS), a statistically significantly greater increase in body weight was seen with icodec NLD compared with IGlar U100 (ETD, 1.22 kg, 95% CI 0.24 to 2.21, *P* = 0.01).

Hypoglycemic events over 21 weeks (on-treatment period) are summarized in Table 2. The percentage of participants with one or more level 2 or level 3 hypoglycemic events during this period was 7.4%, 4.0% and 12.0% in the icodec LD, icodec NLD and IGlar U100 groups, respectively, with rates per patient-year of exposure of 0.78, 0.15 and 0.79, respectively. No level 3 (severe) hypoglycemic events were reported in the trial. Similar results were observed for the period from baseline to week 16 (data not shown). The rate and pattern of level 1 hypoglycemia (Figure 2E) over the on-treatment period were similar across all groups. The rate and pattern of combined level 2 and level 3 hypoglycemic episodes (Figure 2F)were similar between icodec LD and IGlar U100 groups, and appeared to be lower for the icodec NLD group than for the IGlar U100 group. No initial increase in level 1 or combined level 2 and level 3 hypoglycemia was observed in the icodec LD group.

As summarized in Table 2, the incidence and rates of AEs were similar across treatment groups. Most AEs were mild in severity, and only a small number of AEs in each group were possibly or probably related to treatment, none of which were serious. The most frequent AEs are provided in Supplementary Table S3.

Two participants reported seven serious AEs in the icodec LD group (including one event of acute myocardial infarction), and one participant reported one serious AE (acute myocardial infarction) in the IGlar U100 group (Table 2). Both acute myocardial infarction events were confirmed by adjudication and were assessed as unlikely to be related to the trial products. The participant in the icodec LD group who experienced acute myocardial infarction was withdrawn from the trial; no other discontinuations due to AEs occurred. None of the AEs led to a reduction in the dose of trial medication.

No deaths were reported during the trial. Two participants (4.0%) in the icodec NLD group had hypersensitivity reactions confirmed by adjudication, which were reported as not being related to the trial treatment (one participant had a skin rash with irritation attributed to an adhesive bandage and another had a skin rash at the CGM insertion site). All injection-site reactions reported in the trial were mild (Table 2).

# Discussion

The results of the current trial suggest that, in people with type 2 diabetes receiving daily basal insulin therapy, switching to once-weekly icodec is effective and well tolerated. Compared with switching to once-daily basal insulin IGlar U100, switching to once-weekly icodec displayed similar or greater efficacy regarding the primary endpoint of TIR during weeks 15 and 16. Switching to icodec using an initial 100% loading dose (doubling of the first dose) resulted in statistically significantly longer TIR than switching to IGlar U100. Furthermore, doubling the initial dose did not increase the risk of hypoglycemia at any point during the trial period, and prevented the mild, transient pre-breakfast SMBG elevation observed in those randomized to icodec without a loading dose during the immediate post-switch period; that could lead clinicians or patients to inadvertently perceive that the once-weekly insulin may not be as effective as the previous basal insulin.

Notably, a greater change from baseline in TIR (15.4%-points, corresponding to approximately 3 hours and 42 minutes per day) was observed during weeks 15 and 16 in the icodec LD group (vs. 8.6%-points [2 hours and 4 minutes per day] in the icodec NLD group and 7.6%-points [1 hour and 49 minutes per day] in the IGlar U100 group); this is an important observation given that a 5% increase in TIR is considered a clinically significant improvement in glycemic control,(17) and that TIR improvement has been associated with clinically significant benefits for people with type 2 diabetes (17-22). Moreover, it is important to note that a mean TIR of >70%, a target recommended by the International Consensus on TIR,(17) was achieved in the icodec LD group during the last 2 weeks of treatment. Notably, despite the short trial duration limiting the time patients had to reach target, the HbA1c reductions and proportion of participants who achieved HbA1c <7.0% (<53.0 mmol/mol) with icodec are consistent with the observed increase in percent TIR. There was a statistically significant but small increase in body weight at the end of the trial in the icodec NLD group compared with the IGlar U100 group; this may reflect the numerically higher insulin dose requirement in the former.

In this trial, administration of a loading dose of icodec when switching from daily basal insulin seemed to have prevented the mild and transient elevation of pre-breakfast SMBG levels seen in the icodec NLD group. This may be explained by the molecular characteristics and pharmacokinetic and pharmacodynamic properties of icodec. While the long half-life of icodec makes it suitable for once-weekly dosing, it also extends the time to steady state (by ~3–4 weeks). This could consequently produce an initial mild deterioration in fasting glucose levels in those switching from a prior basal insulin therapy who will have an initial treatment deficit. Pharmacokinetic and pharmacodynamic modeling indicated that using a loading dose of icodec could offset this by ensuring the availability of an adequate albumin-bound inactive reservoir; slow release of icodec molecules would provide effective glucose lowering without an increased risk of hypoglycemia versus once-daily basal insulin. This hypothesis is supported by the results of the current trial, because the rate and pattern of hypoglycemic episodes, irrespective of level, were similar between the icodec LD and IGlar U100 groups both immediately post-switch and throughout the treatment period.

The results from this trial suggest that switching from an existing basal insulin to icodec, with or without a loading dose, provides effective glycemic control with comparable risk of hypoglycemia. It was reassuring that not a single episode of severe hypoglycemia (level 3) was reported for any treatment group throughout the trial duration, and that the time spent below range <3.9 mmol/L [<54 mg/dL]), during weeks 15 and 16 was well below the 4% target recommended by the International Consensus on TIR across all treatment groups.

Results for the other safety parameters measured also show that icodec LD was well tolerated. Most AEs across treatment groups were mild in severity, and most (including the small number of serious AEs) were assessed to be unrelated to treatment. None of the AEs required a reduction in the dose of trial medication, and there were few AEs of special interest.

The strengths of this trial include its randomized, multicenter design and the low treatment discontinuation rate. Additionally, this trial employed CGM and measured TIR as a primary endpoint in a patient population with type 2 diabetes, which is quite unique for comparative insulin studies. TIR is a clinically recognized parameter and internationally accepted TIR targets now exist to guide diabetes management (15; 17; 19). Limitations of the trial include its relatively short duration and the modest sample size. In addition, the trial employed an open-label design; however, the CGM recordings used to analyze the primary endpoint of TIR were blinded to both the investigator and trial participant. The observed differences in TIR at weeks 15 and 16 could be due to minor differences in patient characteristics between treatment groups and the low patient numbers concerned. Although individuals taking metformin, and/or DPP4is and/or SGLT2is were eligible to participate, those who were taking other glucose-lowering agents and patients with certain comorbidities were precluded from participation, limiting the generalizability of the results.

The potential to administer basal insulin once weekly, thereby reducing the number of injections, has important implications for diabetes management. Research shows that people with diabetes would welcome such a reduction to improve convenience and quality of life; consequently, it may help to improve adherence and overall glycemic control further (11). In a study by Peyrot *et al*., 27.6% of people with diabetes (*n* = 1530) described “taking insulin at prescribed time or with meals every day” as difficult, and 92.5% of them expressed a wish for good control with “insulin [that did] not [need to be] injected every day” (6). Data from studies evaluating glucagon-like peptide-1 receptor agonists demonstrate that once-weekly administration of these agents is associated with improved treatment satisfaction and medication-taking behavior (23-25). In type 2 diabetes, medication adherence and timely insulin initiation are critical for maintaining glycemic control and reducing diabetes-related complications and associated healthcare resource utilization (26-30).

Overall, the safety and glycemic efficacy of icodec seen in this first phase 2 trial with icodec in basal-insulin-treated participants reflect the flindings of two completed treat-to-target trials with icodec in insulin-naïve people with type 2 diabetes (clinicaltrials.gov identifiers NCT03751657 and NCT03951805) (14). Taken together, these phase 2 trial results suggest effective glycemic control and comparable safety of icodec versus IGlar U100 in a broad patient population with type 2 diabetes, with the major clinical value of reducing the number of weekly basal insulin injections from seven to only one.

In conclusion, in a patient population with type 2 diabetes receiving daily basal insulin therapy, the use of a loading dose when switching to once-weekly icodec resulted in effective glycemic control without a transient elevation of fasting glucose levels during the switch and without increasing the risk of clinically relevant hypoglycemia, compared with IGlar U100. These results will be considered when switching to once-weekly insulin icodec in the phase 3 clinical development program.

# Acknowledgments. The authors thank Dr Gemma Rogers of Oxford PharmaGenesis, Oxford, UK (supported by Novo Nordisk), for provided writing assistance. Dr Harpreet Bajaj is the guarantor for this report and takes full responsibility for the work as a whole, including access to data, and the decision to submit and publish the manuscript.

**Funding.** Novo Nordisk funded the trial and was responsible for trial design and data analysis.

# Duality of Interest. H.S.B. has received speaking fees from AstraZeneca, Eli Lilly, Janssen, Merck and Novo Nordisk, and research funding paid to LMC Healthcare for serving as principal investigator on clinical trials from Amgen, AstraZeneca, Boehringer Ingelheim, Ceapro, Eli Lilly, Gilead, Janssen, Kowa Pharmaceuticals Co. Ltd, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Sanofi and Tricida. R.M.B. has received research support from, consulted for, or has been on a scientific advisory board for Abbott Diabetes Care, Ascensia, Dexcom, Eli Lilly, Hygieia, Johnson & Johnson, Medtronic, Novo Nordisk, Onduo, Roche, Sanofi and United Healthcare. R.M.B.’s employer, non-profit HealthPartners Institute, contracts for his services, and no personal income goes to him. M.J.D. has acted as a consultant, advisory board member and speaker for AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Merck Sharp & Dohme, Novo Nordisk and Sanofi-Aventis, an advisory board member for Gilead Sciences Ltd and Servier, and as a speaker for Mitsubishi Tanabe Pharma Corporation, Napp and Takeda Pharmaceuticals International Inc. She has received grants in support of investigator and investigator-initiated trials from AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk and Sanofi-Aventis. I.L. received research funding, advisory/consulting fees, and/or other support from AstraZeneca, Boehringer Ingelheim, Eli Lilly, GI Dynamics, Intarcia, Intercept Pharmaceuticals, Janssen, MannKind, Merck, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi, Target Pharma, Valeritas and Zealand Pharma. P.A.S. received research support to his institution from Allergan, Novo Nordisk and ViaCyte; as chair of Diabetes Canada Clinical Practice Guidelines, he does not provide consulting or speaking services to, and receives no personal fees from, industry partners. R.J.S. serves on speaker bureaus for AstraZeneca and Novo Nordisk, and serves on advisory panels for Novo Nordisk. R.T. received lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi, and has participated in advisory panels for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi. J.R. has participated in advisory panels for Applied Therapeutics, Boehringer Ingelheim, Eli Lilly, Intarcia, Janssen, Novartis, Novo Nordisk, Oramed and Sanofi. He has received research support from Eli Lilly, Genentech, GlaxoSmithKline, Intarcia, Janssen, Merck & Co, Novo Nordisk, Oramed, Pfizer and Sanofi. A.C., A.G. and J.I. are employees of Novo Nordisk; A.C. and A.G. hold share options and/or shares. The trial was sponsored by Novo Nordisk (clinicaltrials.gov identifier: NCT03922750).

# Author Contributions. All authors had full access to all data, were responsible for data interpretation and manuscript preparation, and had final responsibility for the decision to submit for publication.

## Data Sharing Statement. The data sets generated during and/or analyzed during the current trial are available from the corresponding author on reasonable request.

**Prior Presentation.** This study was previously presented as an e-poster presentation during the EASD 56th Annual Meeting 21–25 September 2020. The abstract and e-poster are available at: <https://www.easd.org/virtualmeeting/home.html#!resources/efficacy-and-safety-of-switching-to-insulin-icodec-a-once-weekly-basal-insulin-vs-insulin-glargine-u100-in-patients-with-type-2-diabetes-inadequately-controlled-on-oads-and-basal-insulin-4358d1c1-7060-43e4-8016-b699cfb3da32>. Last accessed 15 November 2020.

# References

1. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020;43:S98-s110

2. Nyenwe EA, Jerkins TW, Umpierrez GE, et al. Management of Type 2 Diabetes: Evolving Strategies for the Treatment of Patients with Type 2 Diabetes. Metabolism 2011;60:1-23

3. Ross S, Tildesley H, Ashkenas J. Barriers to Effective Insulin Treatment: The Persistence of Poor Glycemic Control in Type 2 Diabetes. Curr Med Res Opin 2011;27 Suppl 3:13-20

4. Escalada J, Orozco-Beltran D, Morillas C, et al. Attitudes Towards Insulin Initiation in Type 2 Diabetes Patients among Healthcare Providers: A Survey Research. Diabetes Res Clin Pract 2016;122:46-53

5. Karter AJ, Subramanian U, Saha C, et al. Barriers to Insulin Initiation: The Translating Research into Action for Diabetes Insulin Starts Project. Diabetes Care 2010;33:733-735

6. Peyrot M, Barnett AH, Meneghini LF, et al. Insulin Adherence Behaviours and Barriers in the Multinational Global Attitudes of Patients and Physicians in Insulin Therapy Study. Diabetic Medicine 2012;29:682-689

7. Okemah J, Peng J, Quiñones M. Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review. Adv Ther 2018;35:1735-1745

8. Donnelly LA, Morris AD, Evans JMM, et al. Adherence to Insulin and Its Association with Glycaemic Control in Patients with Type 2 Diabetes. QJM 2007;100:345-350

9. Cheng AYY, Patel DK, Reid TS, et al. Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different. Adv Ther 2019;36:1018-1030

10. Hernando VU, Pablo FJ. Efficacy and Safety of the Second Generation Basal Insulin Analogs in Type 2 Diabetes Mellitus: A Critical Appraisal. Diabetes Metab Syndr 2019;13:2126-2141

11. Polonsky WH, Fisher L, Hessler D, et al. Patient Perspectives on Once-Weekly Medications for Diabetes. Diabetes Obes Metab 2011;13:144-149

12. Hövelmann U, Brønsted L, Kristensen NR, et al. Insulin Icodec, an Insulin Analog Suited for Once-Weekly Dosing in Type 2 Diabetes. Diabetes 2020;69 (Supplement 1):237-OR

13. Nishimura E KT, Hubalek F, et al. Molecular and Biological Properties of Insulin Icodec, a New Insulin Analog Designed to Give a Long Half-Life Suitable for Once-Weekly Dosing. Diabetes 2020;69 (Supplement 1): 236-OR.

14. Rosenstock J, Bajaj HS, Janež A, et al. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. N Engl J Med 2020;10.1056/NEJMoa2022474

15. 6. Glycemic Targets: Standards of Medical Care in Diabetes—2019. Diabetes Care 2019;42:S61-S70

16. Little RJA, Rubin DB. *Statistical Analysis with Missing Data*. New York, John Wiley & Sons, 1987

17. Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations from the International Consensus on Time in Range. Diabetes Care 2019;42:1593-1603

18. Beck RW, Bergenstal RM, Cheng P, et al. The Relationships between Time in Range, Hyperglycemia Metrics, and Hba1c. J Diabetes Sci Technol 2019;13:614-626

19. Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care 2019;42:400-405

20. Lu J, Ma X, Shen Y, et al. Time in Range Is Associated with Carotid Intima-Media Thickness in Type 2 Diabetes. Diabetes Technol Ther 2020;22:72-78

21. Lu J, Ma X, Zhou J, et al. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, with Diabetic Retinopathy in Type 2 Diabetes. Diabetes Care 2018;41:2370-2376

22. Vigersky RA, McMahon C. The Relationship of Hemoglobin A1c to Time-in-Range in Patients with Diabetes. Diabetes Technol Ther 2019;21:81-85

23. Drucker DJ, Buse JB, Taylor K, et al. Exenatide Once Weekly Versus Twice Daily for the Treatment of Type 2 Diabetes: A Randomised, Open-Label, Non-Inferiority Study. Lancet 2008;372:1240-1250

24. Nguyen H, Dufour R, Caldwell-Tarr A. Glucagon-Like Peptide-1 Receptor Agonist (Glp-1ra) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population. Adv Ther 2017;34:658-673

25. Takase T, Nakamura A, Yamamoto C, et al. Improvement in Treatment Satisfaction after Switching from Liraglutide to Dulaglutide in Patients with Type 2 Diabetes: A Randomized Controlled Trial. J Diabetes Investig 2019;10:699-705

26. Banerji MA, Dunn JD. Impact of Glycemic Control on Healthcare Resource Utilization and Costs of Type 2 Diabetes: Current and Future Pharmacologic Approaches to Improving Outcomes. Am Health Drug Benefits 2013;6:382-392

27. Boye KS, Curtis SE, Lage MJ, et al. Associations between Adherence and Outcomes among Older, Type 2 Diabetes Patients: Evidence from a Medicare Supplemental Database. Patient Prefer Adherence 2016;10:1573-1581

28. García-Pérez LE, Alvarez M, Dilla T, et al. Adherence to Therapies in Patients with Type 2 Diabetes. Diabetes Ther 2013;4:175-194

29. Khunti K, Millar-Jones D. Clinical Inertia to Insulin Initiation and Intensification in the UK: A Focused Literature Review. Prim Care Diab 2017;11:3-12

30. Paul SK, Klein K, Thorsted BL, et al. Delay in Treatment Intensification Increases the Risks of Cardiovascular Events in Patients with Type 2 Diabetes. Cardiovascular diabetology 2015;14:100-100

# Tables and figure legends

## Table 1–Baseline demographics and clinical characteristics

|  | **Icodec LD (*n* = 54)** | **Icodec NLD (*n* = 50)** | **IGlar U100 (*n* = 50)** | **Total (*N* = 154)** |
| --- | --- | --- | --- | --- |
| Age, years | 62.4 ± 7.2 | 62.1 ± 8.2 | 60.5 ± 7.9 | 61.7 ± 7.8 |
| Male, *n* (%) | 39 (72.2%) | 39 (78.0%) | 33 (66.0%) | 111 (72.1%) |
| Duration of type 2 diabetes, years | 13.8 ± 7.7 | 16.8 ± 8.2 | 14.8 ± 8.1 | 15.1 ± 8.1 |
| Ethnicity, *n* (%) |  |  |  |  |
| White | 46 (85.2%) | 39 (78.0%) | 44 (88.0%) | 129 (83.8%) |
| Asian | 4 (7.4%) | 9 (18.0%) | 3 (6.0%) | 16 (10.4%) |
| Black or African–American | 3 (5.6%) | 2 (4.0%) | 3 (6.0%) | 8 (5.2%) |
| Native Hawaiian or other Pacific Islander | 1 (1.9%) | 0 | 0 | 1 (0.6%) |
| BMI, kg/m2 | 30.2 ± 4.3 | 29.0 ± 4.1 | 30.3 ± 5.0 | 29.8 ± 4.5 |
| FPG, mmol/L | 7.9 (1.9)\* | 8.0 (2.3) | 8.2 (2.0)† | 8.0 (2.1) |
| FPG, mg/dL | 142 ± 34\* | 144 ± 41 | 148 ± 36† | 144 ± 37 |
| HbA1c, % | 7.8% (0.7%) | 7.9% (0.7%) | 7.9% (0.7%) | 7.9% (0.7%) |
| HbA1c, mmol/mol | 62.0 (7.4) | 63.3 (8.0) | 63.2 (7.8) | 62.8 (7.7) |
| TIR at baseline, % | 58.9% (23.2%) | 54.5% (20.2%) | 58.7% (21.5%) | 57.4% (21.7%) |
| Total insulin dose‡ (CV%), U  | 22.5 (61.0%) | 24.5 (47.7%) | 24.0 (49.2%) | 23.6 (52.8%) |
| Basal insulin at screening, *n* (%) |  |  |  |  |
| Insulin degludec | 4 (7.4%) | 15 (30.0%) | 7 (14.0%) | 26 (16.9%) |
| Insulin detemir | 9 (16.7%) | 3 (6.0%) | 1 (2.0%) | 13 (8.4%) |
| Insulin glargine U100 | 32 (59.3%) | 23 (46.0%) | 37 (74.0%) | 92 (59.7%) |
| Insulin glargine U300 | 9 (16.7%) | 8 (16.0%) | 5 (10.0%) | 22 (14.3%) |
| NPH (isophane) insulin | 0 | 1 (2.0%) | 0 | 1 (0.6%) |

All data are mean (SD) unless otherwise stated. All percentages are subject to rounding. CV%, coefficient of variation; FPG, fasting plasma glucose; icodec LD, insulin icodec with an initial 100% loading dose; icodec NLD, insulin icodec with no loading dose; insulin glargine U100, insulin glargine 100 U/mL; insulin glargine U300, insulin glargine 300 U/mL; SD, standard deviation; TIR, time in range; U, units. \**n* = 52. †*n* = 49. ‡Geometric mean.

## Table 2–On-treatment hypoglycemic episodes and adverse events, including adverse events of special interest (SAS; *N* = 154)

|  | Icodec LD (*n* = 54, 21.8 PYE) | Icodec NLD (*n* = 50, 20.3 PYE) | IGlar U100 (*n* = 50, 20.2 PYE) | RR (95% CI)\* Icodec LD/IGlar U100 | RR (95% CI)\* Icodec NLD/IGlar U100 |
| --- | --- | --- | --- | --- | --- |
| *n* (%) | Events | Rate\* | *n* (%) | Events | Rate | *n* (%) | Events | Rate |  |  |
| Hypoglycemic episodes |  |  |  |  |  |  |  |  |  |  |  |
| Hypoglycemia ‘alert’ value (level 1)† | 19 (35.2%) | 83 | 3.809 | 26 (52.0%) | 87 | 4.29 | 22 (44.0%) | 76 | 3.77 | 0.94 (0.44; 1.98) | 1.10 (0.51; 2.35) |
| Clinically significant (level 2)‡ or severe (level 3) hypoglycemia | 4 (7.4%) | 17 | 0.78 | 2 (4.0%) | 3 | 0.15 | 6 (12.0%) | 16 | 0.79 | 0.87 (0.18; 4.24)  | 0.39 (0.05; 2.80)  |
| Severe hypoglycemia (level 3)§ | 0 | ·· | ·· | 0 | ·· | ·· | 0 | ·· | ·· |  |  |
| AEs |  |  |  |  |  |  |  |  |  |  |  |
| All AEs | 28 (51.9%) | 85 | 3.90 | 30 (60.0%) | 77 | 3.80 | 23 (46.0%) | 76 | 3.77 |  |  |
| Serious AEs | 2 (3.7%) | 7|| | 32.1 | 0 | ·· | ·· | 1 (2.0%)  | 1¶ | 0.05 |  |  |
| Fatal AEs | 0 | ·· | ·· | 0 | ·· | ·· | 0 | ·· | ·· |  |  |
| Severe AEs | 1 (1.9%) | 1 | 4.6 | 1 (2.0%) | 1 | 0.05 | 0 | ·· | ·· |  |  |
| AEs leading to withdrawal | 1 (1.9%) | 1 | 4.6 | 0 |  |  | 0 |  |  |  |  |
| AEs probably related to basal insulin | 1 (1.9%) | 2 | 9.2 | 2 (4.0%) | 5 | 0.247 | 3 (6.0%) | 3 | 0.15 |  |  |
| AEs possibly related to basal insulin | 0 | ·· | ·· | 1 (2.0%) | 1 | 0.05 | 2 (4.0%) | 2 | 0.10 |  |  |
| AEs of special interest |  |  |  |  |  |  |  |  |  |  |  |
| Injection-site reaction# | 1 (1.9%) | 2 | 9.2 | 1 (2.0%) | 4 | 0.20 | 2 (4.0%) | 3 | 0.15 |  |  |
| Hypersensitivity event# | ·· | ·· | ·· | 2 (4.0%) | 2 | 9.9 | ·· | ·· | ·· |  |  |
| MACE# | 1 (1.9%) | 1||\*\* | 4.6 | 0 | ·· | ·· | 1 (2.0%)  | 1¶\*\* | 0.05 |  |  |

The on-treatment period represents the time period during which participants are considered to be exposed to the trial product.
\*The number of hypoglycemic events was analyzed post hoc using a negative binomial regression model with log link. The model included treatment, pre-trial insulin treatment and SGLT2i use as fixed factors, and the logarithm of the time period for which the hypoglycemic episodes were considered as an offset. AE, adverse event; icodec LD, insulin icodec with an initial 100% loading dose; icodec NLD, insulin icodec with no loading dose; IGlar U100, insulin glargine 100 U/mL; MACE, major adverse cardiovascular events; PYE, patient-years of exposure; RR, rate ratio; SAS, safety analysis set. \*Rate: number of events per patient-year of exposure. †Hypoglycemia ‘alert’ value (level 1): blood glucose value <3.9 mmol/L (<70 mg/dL) and ≥3.0 mmol/L (≥54 mg/dL) confirmed by blood glucose meter. ‡Clinically significant hypoglycemia (level 2): blood glucose value <3.0 mmol/L (<54 mg/dL). §Severe hypoglycemia (level 3): hypoglycemia with severe cognitive impairment requiring external assistance for recovery. ||Acute myocardial infarction (confirmed by adjudication), fall, joint injury and upper limb and two facial bone fractures in one patient; muscle abscess in one patient. ¶Myocardial infarction (confirmed by adjudication). #Independently adjudicated and confirmed. \*\*Also included as serious AEs.

## Figure 1–Time in range during the last 2 weeks of the treatment period (FAS)

TIR was the primary endpoint. FAS, full analysis set; icodec LD, insulin icodec with an initial 100% loading dose; icodec NLD, insulin icodec with no loading dose; IGlar U100, insulin glargine 100 U/mL; TAR, time above range; TBR, time below range; TIR, time in range.

## Figure 2–Key parameters during the trial

*A*: Mean change in HbA1c from baseline to week 16 (FAS).

*B*: Mean change in FPG from baseline to week 16 (FAS).

*C*: Mean pre-breakfast SMBG levels over time (FAS).

*D*: Mean weekly insulin dose over time (FAS).

*E*: Cumulative number of level 1 (‘alert’ value) hypoglycemic episodes per patient (SAS).

F: Cumulative number of level 2 (clinically significant) or level 3 (severe) hypoglycemic episodes per patient (SAS).

Observed data. Panels A, B and C: mean (symbol) ± standard error of the mean. Panel D: geometric mean (symbol) ± standard error of the mean on log-scale back transformed. For panel C, SMBG was assessed with a blood glucose meter as plasma equivalent of capillary whole blood glucose. For panel D, the dose for a given visit represents the total dose during the preceding week, and weekly IGlar U100 doses were derived as seven times the average daily dose during the preceding week. FAS, full analysis set; FPG, fasting plasma glucose; icodec LD, insulin icodec with an initial 100% loading dose; icodec NLD, insulin icodec with no loading dose; IGlar U100, insulin glargine 100 U/mL; SAS, safety analysis set; SMBG, self-measured blood glucose; U, units. \*Estimated mean values and the corresponding CI at week 16 derived based on multiple imputation.